Background: Once-daily extended-release (XR) antiepileptic drugs (AEDs) offer potential adherence and tolerability advantages over their BID immediate-release (IR) counterparts. However, patients with epilepsy will inevitably be at least occasionally nonadherent with a prescribed dosing regimen, regardless of formulation. Although perturbations in plasma concentrations due to dosing irregularities may have clinical consequences for AEDs with concentration-response relationships, clinical studies that deliberately expose patients to specific dosing irregularities in order to assess the effect on plasma concentrations and determine appropriate corrective actions would be unethical. Methods: Computer simulation was used to assess the impact of irregular dosing on topiramate (TPM) concentrations in noninduced (monotherapy/neutral cotherapy) and induced (adjunctive therapy with enzyme-inducing AEDs) states using a population pharmacokinetic (PK) model developed to predict steady-state plasma concentration-time profiles produced by once-daily Trokendi XR ® (extended-release topiramate capsules, Supernus Pharmaceuticals) and BID TPM-IR.
Introduction
Dosing irregularities are common problems in managing acute and chronic diseases. A retrospective analysis of dosing irregularities in chronic disease found that up to 42% of patients did not take medication as prescribed; reasons cited for nonadherence included forgetting doses, forgetting refills, side effects, and cost [1] . In epilepsy, as many as seven in ten patients have reported missing doses of antiepileptic drugs (AEDs) at some time during treatment [2] . A more recent patient survey found that 66% of patients reported omitting doses at least once a Epilepsy & Behavior 52 (2015) [31] [32] [33] [34] [35] [36] month [3] . Patients typically cite forgetfulness as the most common cause of nonadherence [3, 4] . Although patients and physicians agreed that efficacy and safety/tolerability are the most important attributes in AED selection, patients ranked dosing convenience as the next most important attribute [4] .
Medication adherence declines as daily dose frequency increases [5] ; less frequent dosing simplifies the pill-taking regimen and may improve adherence during chronic therapy [6, 7] . A twice-daily (BID) immediaterelease (IR) therapy reformulated as a once-daily (QD) extendedrelease (XR) AED that slows AED absorption can prolong the dosing interval and minimize fluctuations in plasma concentrations [8] , which may have positive effects on adherence, tolerability, and effectiveness.
Despite the potential advantages of XR formulations, clinicians may be hesitant to switch patients with epilepsy from an IR AED dosed BID to its XR counterpart dosed QD based on the belief that a dosing error involving 100% of the total daily dosage has a greater impact on plasma concentrations than a dosing error involving 50% of the total daily dosage [9] . However, such a perspective does not take into account the potential for XR AEDs to maintain therapeutic plasma concentrations for longer intervals due to slowed drug input and administration of a single large dose rather than multiple smaller doses. In contrast to expectations, the characteristics of an XR AED can blunt the impact of dosing errors on plasma concentrations.
Trokendi XR ® (extended-release topiramate capsules, Supernus Pharmaceuticals, Inc.) is a novel once-daily formulation of topiramate (TPM). The specific combination of IR and XR beads using the Microtrol® drug delivery technology slows TPM absorption from Trokendi XR more than 20-fold relative to the morning TPM-IR dose [10] . A randomized crossover study in volunteers comparing 200 mg of once-daily (QD) Trokendi XR to 100 mg BID TPM-IR (Topamax®, Janssen Pharmaceuticals) demonstrated that QD Trokendi XR is bioequivalent to BID TPM-IR [11] , but significantly reduces peak-trough fluctuation for more constant plasma concentrations over the dosing interval. However, this study measured steady-state concentrations in conditions of adherent dosing. Ethical considerations would make it difficult to justify a clinical study in which patients with epilepsy are deliberately exposed to irregularities in AED dosing. However, population pharmacokinetic (PK) modeling and simulation is a powerful tool that can accurately predict dosing-related changes in plasma concentration-time profiles. This technique was used to compare the effects of delayed, omitted, and doubled doses of QD Trokendi XR and BID TPM-IR. In addition, the simulated steady-state PK profiles of QD Trokendi XR and QD TPM-IR were compared since the long half-life of TPM has been cited as justification for QD dosing of TPM-IR in some patients (e.g., receiving TPM as monotherapy or adjunctively with noninducing AEDs) [12] .
Materials and methods
Population PK modeling and simulation was performed using nonlinear mixed-effects modeling (NONMEM, ICON Development Solutions; PLTTools, P Less Than Company). A linear two-compartment PK model with first-order elimination from the central compartment was initially developed. This primary structural model used TPM concentration-time data collected with intensive PK sampling over a 168-hour postdose period in a single-dose, randomized sequence (fed/fasted) crossover study in healthy adult volunteers (ages 18-55 years, N = 31). A final population PK model was developed using TPM plasma concentration-time data from intensive PK sampling on three occasions in adult patients with epilepsy (ages 19-65 years, N = 62). These patients were receiving stable BID TPM-IR with neutral cotherapy (i.e., monotherapy or adjunctive therapy with noninducing AEDs, n = 49) or adjunctive enzyme-inducing AEDs (EIAEDs, n = 13) and were switched to identical total daily dosages of QD Trokendi XR. Release of AED from the dosage unit and subsequent absorption in the gut was modeled with a first-order rate constant and absorption lag. Covariates incorporated into the final model included concomitant use of EIAEDs and body weight (see Supplemental Information for parameter estimates used in the final model). Subsequent model validation included visual inspection of model graphics for goodness of fit and bootstrap analysis of 500 datasets obtained from the original dataset using sampling with replacement.
The population PK model was used to simulate steady-state TPM plasma concentration-time profiles resulting from different dosing scenarios, comparing adherent and nonadherent dosing in neutral and induced states. In these simulations, typical values of model parameters were used to produce a single concentration-time profile for each dosing scenario by setting the variance of within-and between-subject terms to zero. The resulting profile represented the central tendency of the population data. Adherent dosing assumed administration of 200-milligram TPM-IR in equally divided doses every 12 h (100 mg Q12hr) and administration of 200 mg Trokendi XR as a single daily dose every 24 h (200 mg QD). Nonadherent dosing scenarios were 1) a dose administered 4, 8, 12, 16, or 24 h late, with the next dose administered as scheduled; 2) a missed dose that was recovered by adding the omitted dose to the next scheduled dose; and 3) a single doubled dose. For the scenario of dosing 24 h late, the simulation assumed that one dose of QD Trokendi XR (200 mg) is omitted vs. two 100-mg doses of Q12hr TPM-IR (for a total daily dose of 200 mg) before scheduled dosing resumed. Predicted C min and/or C max concentrations for each nonadherent dosing scenario were compared with predicted concentrations for adherent dosing; percent fluctuation was calculated as: [(C max,ss 0-24 − C min,ss 0-24 ) / C avg,ss 0-24 ] × 100%. The steady-state concentration-time profile for QD dosing of TPM-IR was also simulated.
Results

Simulated vs. observed TPM plasma concentration-time profiles
To examine the predictability of the final population PK model, simulated concentration-time profiles were compared with observed mean dose-normalized (200 mg/day) concentration-time data at steady state from patients with epilepsy. The population PK model closely replicated the observed data ( 
Late dosing simulations
The predicted effects (relative to adherent dosing) of increasingly prolonged dosing delays of a single dose are summarized in Table 1 . Simulations for Q12hr TPM-IR assumed a delay in the first daily dose with the second dose being administered as scheduled; modeling of 12-and 24-hour delays assumed a doubling and trebling (respectively) of the TPM-IR dose (recovered dose plus scheduled dose). Modeling of the 16-hour delay assumed that the two recovered doses (total, 200 mg) would be administered 4 h after the day's second dose should have been administered. In the case of QD Trokendi XR, simulation of 24-hour dosing delay assumed simultaneous administration of recovered dose and scheduled dose (total, 400 mg). In these simulations, predicted changes in TPM plasma concentrations followed a pattern of increasingly larger decrements in trough (C min ) levels and increasingly larger increments in peak (C max ) concentrations as the interval between an omitted dose and recovered dose increased.
QD Trokendi XR and Q12hr TPM-IR were not substantially different across the range of dosing delays in terms of predicted decrements in trough concentrations. Relative to adherent dosing, changes in C min concentrations in the neutral state ranged from − 6% to −27% with QD Trokendi XR dose delays and −9% to −31% with Q12hr TPM-IR. With EIAEDs in the model, C min concentration changes ranged from −10% to −39% (QD Trokendi XR) and −15% to −45% (Q12hr TPM-IR).
The 12-hour dosing delay was an inflection point for differences between QD Trokendi XR and Q12hr TPM-IR in that peak concentrations following dose delay/recovery were substantially greater with Q12hr TPM-IR when delays exceeded 12 h (Table 1, Fig. 2 ). Compared with adherent dosing, the predicted changes in C max ranged from +3% to +14% with QD Trokendi XR vs. +2% to +30% with Q12hr TPM-IR in neutral conditions and + 5% to + 25% (QD Trokendi XR) vs. + 2% to + 53% (Q12hr TPM-IR) in the induced state. After TPM-IR or Trokendi XR dosing resumed, simulated C max was higher than steady-state C max ; the magnitude of the "overshoot" was greater with TPM-IR than with Trokendi XR (Fig. 2) .
Overall, perturbations in TPM concentrations were substantially greater in induced vs. neutral conditions for both QD Trokendi XR and Q12hr TPM-IR. However, even in induced patients, predicted changes in C min and C max associated with QD Trokendi XR dosing delays were generally smaller than with Q12hr TPM-IR.
Simulations of an omitted dose
In the simulation of an omitted dose, the interval between last administered dose and dose recovery was 48 h for QD Trokendi XR and 24 h for Q12hr TPM-IR. Following the missed dose, the subsequent dose recovery represented 200% of the total daily dose for Trokendi XR and 100% for TPM-IR. Predicted changes from adherent dosing for C min and C max are shown in Table 2 ; plasma concentration-time profiles are depicted in Fig. 3 . Despite the twofold differences in the time interval and magnitude of recovered dose, formulations differed b10% in terms of C min and C max changes vs. adherent dosing, regardless of metabolic state.
Simulations of a doubled dose
This scenario assumed that the dose intervals were correct but one dose was doubled to 100% of the total daily dose for TPM-IR and 200% of the total daily dose for Trokendi XR. Predicted plasma concentrationtime profiles are shown in Fig. 4 . Increases in peak TPM concentration (vs. adherent dosing) following a doubled dose of Trokendi XR or TPM-IR were comparable in both the neutral (+28% and +26%, respectively) and the induced (+41% and +39%, respectively) states. Table 3 . Relative to QD Trokendi XR, QD TPM-IR was associated with a higher C max (+ 14%), lower C min (−34%), and lower C avg (−11%) in neutral conditions. As a result, fluctuation was 64% for QD TPM-IR vs. 18% for QD Trokendi XR.
Simulations of QD dosing
Discussion
Predicted changes in TPM plasma concentrations for nonadherent vs. adherent dosing suggest that common dosing errors with QD Trokendi XR would likely pose no greater clinical risks than with Q12hr TPM-IR. Predicted reductions in trough TPM concentrations with delayed QD Trokendi XR dosing were not as pronounced as with Q12hr TPM-IR. When simulations assumed that dosing would continue as scheduled, peak concentrations were typically blunted with QD Trokendi XR, resulting in less "overshoot" in C max when compared with C max for Q12hr TPM-IR. With TPM-IR, C max increases of 30% (noninduced/neutral) and N 50% (induced) after dose recovery could be clinically notable. Unlike the late-dosing simulations in which both formulations were delayed the same length of time, the omitted-dose scenario imposed more severe conditions on Trokendi XR in terms of TPM concentration fluctuation. The time between dose administration and recovery was longer for Trokendi XR (48 h vs. 24 h), while the magnitude of omitted (100% vs. 50%, respectively) and subsequently restored (200% vs. 100%, respectively) doses were greater. Nonetheless, the omitted-dose simulation showed that reductions in trough levels and subsequent increases in peak levels relative to adherent dosing were similar for QD Trokendi XR and Q12hr TPM-IR. Similarly, in the scenario of a doubled dose, increases in peak TPM concentration were of comparable magnitude vs. adherent dosing for both formulations, providing reassurance that a missed Trokendi XR dose can be restored at any time within the dosing interval [11] . With the inclusion of EIAED coadministration in the simulations, comparisons between formulations showed the same trends as in the neutral state, although plasma concentration changes were generally of greater magnitude with both formulations. The simulations assumed Q12hr dosing for TPM-IR in accordance with BID dosing recommendations in Topamax prescribing information [13] . However, TPM has a long elimination half-life, substantially exceeding 24 h in the absence of enzyme induction [14] . Based on the premise that the dosing interval should be equal to drug half-life, a half-life that exceeds 24 h would seem to support QD dosing of any TPM formulation, at least in patients not receiving EIAEDs. However, in the simulations comparing steady-state PK, 24-hour plasma concentration-time curves were markedly different for QD Trokendi XR and QD TPM-IR. The predicted trough TPM concentration was lower, and the peak concentration was higher with QD TPM-IR, resulting in much greater fluctuation vs. QD Trokendi XR.
Plasma concentration fluctuation is a function of available dose, dosing interval, half-life, and absorption rate. Three of these parameters -dose, dosing interval, half-life -were identical in the simulations comparing QD dosing of Trokendi XR and TPM-IR. Thus, slower drug release reflected by a N 20-fold slower TPM absorption rate with Trokendi XR vs. TPM-IR accounted for the markedly diminished fluctuation of QD Trokendi XR. Although the analysis reported here did not simulate delayed or missed doses if TPM-IR was dosed QD, a markedly lower C min vs. Trokendi XR would be expected after any delay given that the predicted C min was already 34% lower with adherent QD dosing of TPM-IR.
In the case of QD Trokendi XR vs. Q12hr TPM-IR, computer simulations showed that QD Trokendi XR was at least as forgiving as BID TPM-IR, which is counter to expectations that an omitted dose of a QD XR formulation would pose a greater clinical risk than an omitted dose of an IR AED being dosed BID [9] . However, this perception does not take into account the magnitude of administered dose (e.g., 100% for QD XR formulation vs. 50% of total daily dosage for BID IR drug) and controlled drug input of XR formulations such as Trokendi XR. Controlled drug release regulates drug input, produces more constant TPM plasma concentrations, and blunts the impact of irregularities in QD dosing.
Computer simulation is a cost-effective means of systematically evaluating many different permutations of drug administration and has been used to evaluate the PK impact of irregular dosing for several AEDs in order to determine appropriate corrective actions [15] [16] [17] [18] [19] . For ease of illustration, the concentration-time profiles presented in our analysis depict the "typical patient" based on the population mean for each dosing scenario, similar to simulations comparing XR and IR formulations of lamotrigine [19] . As demonstrated with extended-release divalproex dosing [20] , simulations can also incorporate estimates for between-and within-patient variability. This approach generates plasma concentration-time profiles that reflect the predicted range of C min and C max concentrations that could occur with specific scenarios of dosing nonadherence and dosing corrections in the majority of patients. Such information is particularly informative for AEDs, including divalproex, with nonlinear PK, poor correlation between dose and/or plasma concentrations, and relatively narrow therapeutic index. In contrast, TPM exhibits a linear dose-concentration relationship (i.e., at doses N 25 mg) and has a relatively broad reference range [21] .
Although computer simulations cannot replace real-world experience in patients, the simulations presented here are rooted in PK data and intrinsic factors collected from patients with epilepsy in clinical Time, days studies and avoid the potential ethical issues of studies that would deliberately delay or withhold AED doses during treatment. In the case of QD Trokendi XR, simulations showed that TPM concentrations can be restored by administering the delayed/missed dose at any time during the next dosing interval or by adding the omitted dose to the next scheduled dose, regardless of AED cotherapy (neutral or EIAED).
Conclusions
Using a population PK model that was highly predictive of observed steady-state TPM plasma concentrations, simulations that assumed BID (Q12hr) dosing of TPM-IR showed that delays in QD Trokendi XR dosing would be expected to have less effect on TPM plasma concentrations than delays with TPM-IR dosing. After an omitted QD Trokendi XR dose (100% of total daily dose), the predicted reduction in trough concentration was only slightly greater than after an omitted Q12hr TPM-IR dose (50% of total daily dose). Simulations predicted markedly different steady-state plasma concentration-time curves if Trokendi XR and TPM-IR were both dosed QD. In the simulation of steady-state QD dosing, the lower C min concentrations predicted for QD TPM-IR suggested a higher risk of seizures despite adherent QD TPM-IR dosing. Results of simulated doubled dosing showed that TPM levels can be restored by administering a delayed or omitted dose any time within the dosing interval. Simulations showed that predicted increases in peak TPM concentrations following doubled doses were comparable for the two formulations. The impact of delayed, omitted, or doubled doses was consistently greater with enzyme induction. Based on these simulated dosing scenarios, dosing irregularities with once-daily Trokendi XR should pose no greater risk than with BID TPM-IR.
Supplementary data to this article can be found online at http://dx. Time, days [13] .
